Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $53.00 price target on Kymera Therapeutics (NASDAQ: KYMR) following Q1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE